A citation-based method for searching scientific literature

Hisko Oeseburg, Rudolf A de Boer, Hendrik Buikema, Pim van der Harst, Wiek H van Gilst, Herman H W Silljé. Arterioscler Thromb Vasc Biol 2010
Times Cited: 177







List of co-cited articles
627 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
17

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Thomas Nyström, Mark K Gutniak, Qimin Zhang, Fan Zhang, Jens Juul Holst, Bo Ahrén, Ake Sjöholm. Am J Physiol Endocrinol Metab 2004
486
17

Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes.
Antonio Ceriello, Anna Novials, Emilio Ortega, Silvia Canivell, Lucia La Sala, Gemma Pujadas, Katherine Esposito, Dario Giugliano, Stefano Genovese. Diabetes Care 2013
108
15

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
Masayuki Arakawa, Tomoya Mita, Kosuke Azuma, Chie Ebato, Hiromasa Goto, Takashi Nomiyama, Yoshio Fujitani, Takahisa Hirose, Ryuzo Kawamori, Hirotaka Watada. Diabetes 2010
349
14

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
727
13

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
12


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
10

GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.
Hari Hendarto, Toyoshi Inoguchi, Yasutaka Maeda, Noriko Ikeda, Jing Zheng, Ryoko Takei, Hisashi Yokomizo, Eiichi Hirata, Noriyuki Sonoda, Ryoichi Takayanagi. Metabolism 2012
137
10

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Mohammad Hossein Noyan-Ashraf, M Abdul Momen, Kiwon Ban, Al-Muktafi Sadi, Yu-Qing Zhou, Ali M Riazi, Laurie L Baggio, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2009
392
10

The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes.
Antonio Ceriello, Katherine Esposito, Roberto Testa, Anna Rita Bonfigli, Maurizio Marra, Dario Giugliano. Diabetes Care 2011
93
10

Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism.
Dongjuan Wang, Peng Luo, Yabin Wang, Weijie Li, Chen Wang, Dongdong Sun, Rongqing Zhang, Tao Su, Xiaowei Ma, Chao Zeng,[...]. Diabetes 2013
126
9

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
9


Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes.
Antonio Ceriello, Anna Novials, Silvia Canivell, Lucia La Sala, Gemma Pujadas, Katherine Esposito, Roberto Testa, Loredana Bucciarelli, Maurizio Rondinelli, Stefano Genovese. Diabetes Care 2014
48
18





Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction.
Yen-Ta Chen, Tzu-Hsien Tsai, Chih-Chau Yang, Cheuk-Kwan Sun, Li-Teh Chang, Hung-Hwa Chen, Chia-Lo Chang, Pei-Hsun Sung, Yen-Yi Zhen, Steve Leu,[...]. J Transl Med 2013
71
11

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
8

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
8

Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.
Battsetseg Batchuluun, Toyoshi Inoguchi, Noriyuki Sonoda, Shuji Sasaki, Tomoaki Inoue, Yoshinori Fujimura, Daisuke Miura, Ryoichi Takayanagi. Atherosclerosis 2014
103
7

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
Gian Paolo Fadini, Elisa Boscaro, Mattia Albiero, Lisa Menegazzo, Vera Frison, Saula de Kreutzenberg, Carlo Agostini, Antonio Tiengo, Angelo Avogaro. Diabetes Care 2010
253
7

Cardioprotective effects of exenatide against oxidative stress-induced injury.
Guanglei Chang, Dongying Zhang, Hui Yu, Peng Zhang, Ying Wang, Aihua Zheng, Shu Qin. Int J Mol Med 2013
49
14


Cardiovascular biology of the incretin system.
John R Ussher, Daniel J Drucker. Endocr Rev 2012
364
7

Oxidative stress and diabetic complications.
Ferdinando Giacco, Michael Brownlee. Circ Res 2010
7

The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.
Hiroki Fujita, Tsukasa Morii, Hiromi Fujishima, Takehiro Sato, Tatsunori Shimizu, Mihoko Hosoba, Katsushi Tsukiyama, Takuma Narita, Takamune Takahashi, Daniel J Drucker,[...]. Kidney Int 2014
162
7


Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner.
Eri Mukai, Shimpei Fujimoto, Hiroki Sato, Chitose Oneyama, Rieko Kominato, Yuichi Sato, Mayumi Sasaki, Yuichi Nishi, Masato Okada, Nobuya Inagaki. Diabetes 2011
70
8

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Kiwon Ban, Kyoung-Han Kim, Chan-Kyung Cho, Meghan Sauvé, Eleftherios P Diamandis, Peter H Backx, Daniel J Drucker, Mansoor Husain. Endocrinology 2010
158
6

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
Minsuk Kim, Mathew J Platt, Tadao Shibasaki, Susan E Quaggin, Peter H Backx, Susumu Seino, Jeremy A Simpson, Daniel J Drucker. Nat Med 2013
295
6

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Junichi Matsubara, Seigo Sugiyama, Koichi Sugamura, Taishi Nakamura, Yukio Fujiwara, Eiichi Akiyama, Hirofumi Kurokawa, Toshimitsu Nozaki, Keisuke Ohba, Masaaki Konishi,[...]. J Am Coll Cardiol 2012
209
6

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
6

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
Tracey Gaspari, HongBin Liu, Iresha Welungoda, Yunshan Hu, Robert E Widdop, Lotte B Knudsen, Richard W Simpson, Anthony E Dear. Diab Vasc Dis Res 2011
116
6

Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia.
Shinichiro Teramoto, Nobukazu Miyamoto, Kenji Yatomi, Yasutaka Tanaka, Hidenori Oishi, Hajime Arai, Nobutaka Hattori, Takao Urabe. J Cereb Blood Flow Metab 2011
138
6

Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes.
Takashi Iwai, Satoshi Ito, Kahori Tanimitsu, Shunichi Udagawa, Jun-Ichiro Oka. Neurosci Res 2006
137
5

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
5

Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential antioxidant effects.
Betsy B Dokken, Charles V Piermarini, Mary K Teachey, Michael T Gura, Christian J Dameff, Brian D Heller, Jonida Krate, Aeen M Ashgar, Lauren Querin, Jennifer L Mitchell,[...]. Am J Physiol Heart Circ Physiol 2013
19
26

A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
Mohammad Hossein Noyan-Ashraf, Eric Akihiko Shikatani, Irmgard Schuiki, Ilya Mukovozov, Jun Wu, Ren-Ke Li, Allen Volchuk, Lisa Annette Robinson, Filio Billia, Daniel J Drucker,[...]. Circulation 2013
151
5

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon. Circulation 2004
643
5

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.
Paul Richards, Helen E Parker, Alice E Adriaenssens, Joshua M Hodgson, Simon C Cork, Stefan Trapp, Fiona M Gribble, Frank Reimann. Diabetes 2014
243
5

Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Swenja Kröller-Schön, Maike Knorr, Michael Hausding, Matthias Oelze, Alexandra Schuff, Richard Schell, Stephan Sudowe, Alexander Scholz, Steffen Daub, Susanne Karbach,[...]. Cardiovasc Res 2012
128
5

Cardiovascular actions of incretin-based therapies.
John R Ussher, Daniel J Drucker. Circ Res 2014
234
5


Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.
Leo Timmers, José P S Henriques, Dominique P V de Kleijn, J Hans Devries, Hans Kemperman, Paul Steendijk, Cees W J Verlaan, Marjolein Kerver, Jan J Piek, Pieter A Doevendans,[...]. J Am Coll Cardiol 2009
342
5

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.
Lazaros A Nikolaidis, Dariush Elahi, Teresa Hentosz, Aaron Doverspike, Rhonda Huerbin, Lee Zourelias, Carol Stolarski, You-tang Shen, Richard P Shannon. Circulation 2004
388
5

AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes.
Magali Balteau, Anne Van Steenbergen, Aurélie D Timmermans, Chantal Dessy, Gaetane Behets-Wydemans, Nicolas Tajeddine, Diego Castanares-Zapatero, Patrick Gilon, Jean-Louis Vanoverschelde, Sandrine Horman,[...]. Am J Physiol Heart Circ Physiol 2014
77
6

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.